Revenue Update on Asterias Biotherapeutics Inc(NYSEMKT:AST)

Asterias Biotherapeutics Inc(NYSEMKT:AST) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.27M. Analysts estimated a revenue of $1.14M. Earnings per share were $-0.11. Analysts had estimated an EPS of $-0.19.

In a different note, Chardan Capital said it Initiates Coverage on Asterias Biotherapeutics Inc, according to a research note issued on May 23, 2016. The shares have been rated ‘Buy’ by the firm.

Asterias Biotherapeutics Inc (AST) shares turned negative on Wednesdays trading session with the shares closing down -0.12 points or -4.03% at a volume of 1,23,623. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.99. The peak price level was also seen at $2.99 while the days lowest was $2.85. Finally the shares closed at $2.86. The 52-week high of the shares is $6.4 while the 52-week low is $2.3. According to the latest information available, the market cap of the company is $130 M.

Several Insider Transactions has been reported to the SEC. On Jul 1, 2016, Richard T. Lebuhn (director) purchased 5,000 shares at $2.38 per share price.Also, On Jul 1, 2016, Stephen Lahue Cartt (CEO) purchased 10,000 shares at $2.40 per share price.On Jun 10, 2016, Alfred D Kingsley (director) purchased 4,000 shares at $2.93 per share price, according to the Form-4 filing with the securities and exchange commission.

Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *